Introduction: Principles of therapeutics of fluvastatin

A. Corsini, R. Fumagalli, R. Paoletti, M. R. Soma

Research output: Contribution to journalArticle

Abstract

Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalDrugs of Today
Volume32
Issue numberSUPPL A
Publication statusPublished - 1996

Fingerprint

fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerosis
Cardiovascular Diseases
Blood Vessels
Lipids
Mevalonic Acid
Atherosclerotic Plaques
Therapeutics
Hypercholesterolemia
Intercellular Signaling Peptides and Proteins
Arterial Pressure
Cytokines
Survival
Incidence

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Corsini, A., Fumagalli, R., Paoletti, R., & Soma, M. R. (1996). Introduction: Principles of therapeutics of fluvastatin. Drugs of Today, 32(SUPPL A), 1-12.

Introduction : Principles of therapeutics of fluvastatin. / Corsini, A.; Fumagalli, R.; Paoletti, R.; Soma, M. R.

In: Drugs of Today, Vol. 32, No. SUPPL A, 1996, p. 1-12.

Research output: Contribution to journalArticle

Corsini, A, Fumagalli, R, Paoletti, R & Soma, MR 1996, 'Introduction: Principles of therapeutics of fluvastatin', Drugs of Today, vol. 32, no. SUPPL A, pp. 1-12.
Corsini A, Fumagalli R, Paoletti R, Soma MR. Introduction: Principles of therapeutics of fluvastatin. Drugs of Today. 1996;32(SUPPL A):1-12.
Corsini, A. ; Fumagalli, R. ; Paoletti, R. ; Soma, M. R. / Introduction : Principles of therapeutics of fluvastatin. In: Drugs of Today. 1996 ; Vol. 32, No. SUPPL A. pp. 1-12.
@article{ad484124ca614d00a65d44553b560933,
title = "Introduction: Principles of therapeutics of fluvastatin",
abstract = "Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.",
author = "A. Corsini and R. Fumagalli and R. Paoletti and Soma, {M. R.}",
year = "1996",
language = "English",
volume = "32",
pages = "1--12",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "SUPPL A",

}

TY - JOUR

T1 - Introduction

T2 - Principles of therapeutics of fluvastatin

AU - Corsini, A.

AU - Fumagalli, R.

AU - Paoletti, R.

AU - Soma, M. R.

PY - 1996

Y1 - 1996

N2 - Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.

AB - Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.

UR - http://www.scopus.com/inward/record.url?scp=0029885927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029885927&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029885927

VL - 32

SP - 1

EP - 12

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - SUPPL A

ER -